This company is a global Contract Development and Manufacturing Organization (CDMO) with over 25 years of experience in the pharmaceutical industry. They offer a wide range of services, including development and manufacturing of both biologics and small molecules, spanning areas like ATMPs (Advanced Therapies Medicinal Products), RNA therapies, viral vectors, microbiome live biotherapeutics, and traditional oral solid dosage forms. Key therapy areas include oncology, immunology, and infectious diseases. They hold GMP certifications for various facilities across multiple regions, including the EU and North America. The company is committed to sustainability and ethical business practices. They also offer specialized services such as sterile fill & finish, ophthalmics manufacturing, and analytical services.
IDEBENONE
Idebenone is used in the treatment and manages Alzheimer's, Huntington’s, liver, and heart
diseases. It also treats some inherited disorders including Leber’s hereditary optic neuropathy,
mitochondrial encephalomyopathies that involve nerve and muscle disorders, Duchenne
muscular dystrophy, and Friedreich's ataxia, a nervous system disorder producing gait and
speech problems, and eventually leading toward heart disease and diabetes. Idebenone is
similar to coenzyme Q-10 and a man-made product.
Idebenone is sold under brand names Catena, Raxone, Sovrima, among others.
Takeda Pharmaceutical Company initially developed it for the treatment of Alzheimer's disease
and other cognitive defects but met with limited success. Later, Santhera Pharmaceuticals, a
Swiss co investigated it for the treatment of neuromuscular diseases. In 2010, It was tested for
Friedreich's ataxia and Duchenne muscular dystrophy but it was not approved for the above in
North America or Europe. In 2007, Idebenone was approved by the European Medicines
Agency for use in Leber's hereditary optic neuropathy and received its designation as an orphan
drug.
Dosage and administration
Idebenone is sold as tablets in 300mg strength and taken orally. In the treatment of Alzheimer's
disease, the recommended initial adult dose is 90-120 mg, taken three times a day. In treating
inherited Leber's hereditary optic neuropathy, the dose is 300 mg, taken orally three times per
day with meals for both children and adults. In children, in the treatment of Duchenne muscular
dystrophy, the dose is 900 mg, taken daily for one year.
The price of Idebenone
In the international market, a supply of 20mg of for the ingredient form costs around USD 247.
In India, the consumers have to pay a retail price of USD 2.8 for a supply of 10 tablets of 45mg
strength.
How does it work?
Idebenone has several actions, some of the actions include stimulation of ATP formation,
increasing the antioxidant capacity, scavenging the free radicals, protecting against lipid
peroxidation. It also bypasses the dysfunctional complex I of the mitochondrial respiratory chain.
Finding Idebenone Manufacturers and Suppliers:
The process of finding trusted Idebenone manufacturers and Idebenone suppliers can be made
quicker and more accessible by using Pipelinepharma's online platform, a B2B marketplace that
lets you finalize the deals of pharmaceutical products in a matter of a few clicks. In addition, it is
an easy-to-use online platform to grow your business opportunities.
The robust search engine makes it convenient to search for manufacturers and suppliers of
Idebenone. The search can be further refined with industry-specific filters such as dossier type,
country of origin, GMP approvals, and search criteria for Wholesaler, etc. helping to get in
contact with the preferred manufacturer and supplier readily.
